We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





Noul Demonstrates AI-Driven On-Site Diagnostics Platform at MEDICA 2022

By LabMedica International staff writers
Posted on 15 Nov 2022

Noul Co. More...

, Ltd. (Gyeonggi-do, Korea) is demonstrating the world’s first integrated device featuring fully-automated sample preparation and AI-based diagnosis at the 2022 edition of MEDICA being held from 14 to 17 November in Düsseldorf, Germany.

At MEDICA 2022, Noul is demonstrating miLab, which is the world’s first all-in-one, fully-automated device which can process sample preparation and AI diagnostic in one workflow. miLab integrates cutting edge technologies from computer vision AI, bio, hardware and software engineering. From automated sample preparation to imaging and AI analysis, the miLab platform combines the gold standard in blood diagnostics into a fully automated benchtop platform. Combined with embedded AI and the company’s patented Next Generation Staining and Immunostaining (NGSI) cartridges, miLab provides an accurate analysis in 20 minutes using just 5 uL of blood. NGSI, the patented solid-based staining technology can replace the current liquid-based sample preparation methods and possess the potential to expand applicabilities to other diagnostic areas. NGSI technology eliminates the liquid usage in the sample staining process and can complete it in only a few minutes using a single step stamping method.

miLab provides superior accuracy compared to the competing technologies by combining multi-focus imaging and the state-of-the-art AI algorithm. The company’s AI can perfectly replicate the diagnosis of an expert microscopist without the errors and deviations. miLab’s AI algorithm analyzes multi-layered digital images of smeared blood cells to achieve 99%+ specificity in order to classify and detect parasite-infected cells. Among Noul’s offerings is the miLab Malaria which detects different stages of Plasmodium Falciparum and Plasmodium Vivax species and the miLab BCM which provides a morphology-based white blood cell (WBC) differential and cell count estimations, allowing decentralized health facilities to perform a WBC differential count and CBC estimation.

Related Links:
Noul Co., Ltd.


New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
NGS Cancer Assay
Plasma-SeqSensei Solid Cancer IVD Kit
New
Blood Grouping & Compatibility Reagent
Microcolumn Gel Blood Type Test Card
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.